Sofinnova PartnersVenture CapitalSofinnova Partners surpasses target with €650m fund to back up early-stage biotechSofinnova Partners has closed its new investment fund, Capital XI, at €650m, far exceeding its original target. The early-stage biotech and medtech-focused fund will invest mostly in Series A, but … more ➔
Medicxi FinancingMedicxi announces new €500m biotech investment fundVC specialist Medicxi has closed its oversubscribed €500m Fund V to support existing biopharmaceutical developers, and creating new companies across all development stages. more ➔
chokniti - Adobe StockFinancingVirometix: US$15m for Synthetic VaccinesSwiss biotech Virometix has raised US$15m in fresh funding to accelerate development of its lead pneumococcal vaccine candidate and advance its next-generation synthetic vaccine platform. more ➔
Scripta TherapeuticsFinancingScripta Therapeutics raises $12m to flip the script on drug discoveryOxford-based techbio startup Scripta Therapeutics has emerged from stealth with a biology-first platform targeting the master regulators of disease. more ➔
adobe stock photos - JustlightHypertensionAZ’s baxdrostat mets endpoint in resistant hypertensionAstraZeneca’s baxdrostat cuts 24-hour systolic BP by 14mmHg in resistant hypertension, offering a novel mechanism and major market potential. more ➔
stock.adobe.photos.com - gaviLicencing dealAstraZeneca bolsters obesity portfolio with muscle‑preserving buyAstraZeneca plc acquires SixPeaks Bio Inc to target muscle‑preserving obesity therapies, boosting its pipeline in a US$30 bn fast-growing weight-loss market. more ➔
adobe stock photos - AkuAku mRNA ProductionBreakthrough study reveals stability key for mRNAA landmark discovery by a team of South Korean scientists could transform the way RNA-based vaccines and therapeutics are developed and produced. Researchers led jointly by Professor V. Narry Kim and … more ➔
Adobe stock photos - Dzmitry Obesity medicinesSemaglutide and tirzepatide significantly improve heart healthSemaglutide (Ozempic®) and Tirzepatide (Mounjaro®) not only promote weight loss but also significantly reduce the risk of major cardiovascular events in patients with type 2 diabetes. Real-world evidence … more ➔
Adobe stock photos - Matthew US Pharma PricesEli Lilly and Novo Nordisk slash obesity drug pricesEli Lilly and Novo Nordisk cut US obesity drug prices under Trump’s MFN plan, offering Zepbound, Wegovy and others via Medicare, Medicaid and LillyDirect. more ➔
Parse BiosciencesAI/single cell analysisQIAGEN acquires Parse Biosciences Inc for US$225mBiotech leader QIAGEN NV announced the acquisition of Parse Biosciences for US$225M upfront, plus up to US$55M in milestone payments, expected to close by the end of 2025. more ➔
Sofinnova Partners
Medicxi 
chokniti - Adobe Stock
Scripta Therapeutics
adobe stock photos - Justlight
stock.adobe.photos.com - gavi
adobe stock photos - AkuAku 
Adobe stock photos - Dzmitry 
Adobe stock photos - Matthew 
Parse Biosciences